Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 2,670 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 2,670 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the transaction, the insider owned 46,275 shares of the company’s stock, valued at approximately $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The shares were sold at an average price of $30.60, for a total value of $55,967.40.
• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Price Performance

PHVS stock traded up $0.62 during mid-day trading on Monday, reaching $31.71. The company had a trading volume of 388,815 shares, compared to its average volume of 240,184. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -9.97 and a beta of -2.35. Pharvaris N.V. has a 52 week low of $16.00 and a 52 week high of $33.33. The stock has a 50 day simple moving average of $29.24 and a two-hundred day simple moving average of $27.32.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.

Institutional Trading of Pharvaris

Several hedge funds have recently modified their holdings of PHVS. Tudor Investment Corp ET AL bought a new stake in Pharvaris during the 3rd quarter valued at $1,943,000. Patient Square Capital LP increased its position in shares of Pharvaris by 41.4% during the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after acquiring an additional 101,098 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of Pharvaris in the third quarter worth approximately $4,990,000. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after purchasing an additional 23,743 shares in the last quarter. Finally, Boothbay Fund Management LLC boosted its position in shares of Pharvaris by 735.1% during the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock valued at $3,373,000 after buying an additional 118,994 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on PHVS shares. Citizens Jmp lowered their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.